Methods for the prognosis of and/or determination of the efficacy of a therapeutic regimen for neurological and neurodegenerative diseases and disorders, and associated processes, include using a detectable label to measure levels of alpha-synuclein, wherein the level of the labeled alpha-synuclein in a biological sample obtained from a subject is measured and compared to the alpha-synuclein level from a corresponding normal sample, wherein a change in the alpha-synuclein metabolism of the subject compared to the corresponding normal sample is indicative of the presence or progression of a neurological and neurodegenerative disease or disorder.
METHODS FOR THE DIAGNOSIS AND TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISEASES AND DISORDERS USING LABELED ALPHA SYRUCLEIN